Responses
Abstracts Accepted for Publication
Spondyloarthritis - treatment
AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study
Compose a Response to This Article
Other responses
No responses have been published for this article.